Clinical Trial Update: Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating adalimumab in axial spondyloarthritis with MRI and biomarker analyses; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spondyloarthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Spondyloarthritis | Phase 4 | Status: COMPLETED